Amgen Q2 Earnings Top $10B, Dividend Rises 6% on Growth

**Implied Volatility / Movement:** Amgen Inc. (NASDAQ: AMGN) posted second-quarter revenue exceeding $10 billion, marking a 10% increase from the previous year, as robust sales from multiple drugs offset declines in its bone-health franchise. The company also raised its full-year revenue and adjusted EPS outlook, signaling continued operational strength.

### Catalyst Analysis: Growth Drivers Offset Biosimilar Pressure Amgen's revenue for the quarter surpassed $10 billion, up 10% year-over-year. This growth was fueled by a combined 26% increase in its six identified growth drivers, which now represent nearly 70% of product sales. Key contributors include Repatha, with sales up 37% to $953 million, EVENITY, up 38% to $714 million, and TEZSPIRE, growing 42% to $486 million. The rare disease portfolio saw a 21% rise to $1.6 billion, with UPLIZNA revenue surging 90% to $335 million. Innovative oncology also contributed significantly, with revenue up 18% to approximately $2 billion, boosted by a 115% jump in IMDELLTRA sales to $288 million. However, bone-health products Prolia and XGEVA experienced a 33% sales decline, totaling $1.1 billion, due to biosimilar competition. The company generated $3.5 billion in free cash flow, raised its quarterly dividend 6% to $2.52 per share, and expects 2026 revenue between $38.2 billion and $39.4 billion.

## $AMGN+WL Technical Analysis & Key Risk Watch Key levels for $AMGN+WL (educational): R2 $398.00 · R1 $386.82 · last $385.16 · S1 $382.21 · S2 $372.16.

### Sector Ripple / Impact on Biotechnology Amgen's performance highlights the resilience of diversified biotechnology portfolios against specific product pressures. Investors will monitor similar dynamics in other large-cap biotechs facing patent cliffs or biosimilar challenges, particularly in areas like cardiovascular and oncology treatments.